Considering that STOML2 expression has a strong relationship with the prognosis of pancreatic cancer patients, we further tested the function of STOML2 in GEM resistance, which is the first-line chemotherapy against pancreatic cancer [21]. The gene discussed is STOML2; the disease is familial pancreatic carcinoma.